Double-Blind Study of the Safety of Clopidogrel With and Without a Loading Dose in Combination With Aspirin Compared With Ticlopidine in Combination With Aspirin After Coronary Stenting : The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS), Circulation, vol.102, issue.6, pp.624-633, 2000. ,
DOI : 10.1161/01.CIR.102.6.624
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, vol.345, pp.494-502, 2001. ,
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study, The Lancet, vol.358, issue.9281, pp.527-560, 2001. ,
DOI : 10.1016/S0140-6736(01)05701-4
Variability in Individual Responsiveness to Clopidogrel, Journal of the American College of Cardiology, vol.49, issue.14, pp.1505-1521, 2007. ,
DOI : 10.1016/j.jacc.2006.11.044
Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome, The American Journal of Cardiology, vol.101, issue.8, pp.1088-93, 2008. ,
DOI : 10.1016/j.amjcard.2007.11.065
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study, The Lancet, vol.373, issue.9660, pp.309-326, 2009. ,
DOI : 10.1016/S0140-6736(08)61845-0
Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration, Journal of the American College of Cardiology, vol.56, issue.2, pp.134-177, 2010. ,
DOI : 10.1016/j.jacc.2009.12.071
The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome, Journal of Thrombosis and Haemostasis, vol.79, issue.8, pp.1409-1420, 2009. ,
DOI : 10.1111/j.1538-7836.2009.03500.x
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement, Circulation, vol.121, issue.4, pp.512-520, 2010. ,
DOI : 10.1161/CIRCULATIONAHA.109.885194
Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial, Circulation, vol.111, issue.25, pp.3366-73, 2005. ,
DOI : 10.1161/CIRCULATIONAHA.104.502815
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation, American Heart Journal, vol.153, issue.1, pp.9-16, 2007. ,
DOI : 10.1016/j.ahj.2006.10.010
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes, New England Journal of Medicine, vol.357, issue.20, pp.2001-2016, 2007. ,
DOI : 10.1056/NEJMoa0706482
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes, Circulation, vol.119, issue.19, pp.2553-60, 2009. ,
DOI : 10.1161/CIRCULATIONAHA.109.851949
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel, Journal of Thrombosis and Haemostasis, vol.26, issue.Suppl. 2, pp.2429-2465, 2007. ,
DOI : 10.1111/j.1538-7836.2007.02775.x
Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets: definition and detection of ticlopidine/clopidogrel effects, Thromb Haemost, vol.82, pp.1145-52, 1999. ,
High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes, Journal of the American College of Cardiology, vol.58, issue.5, pp.467-73, 2011. ,
DOI : 10.1016/j.jacc.2011.04.017
Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium, Circulation, vol.123, issue.23, pp.2736-2783, 2011. ,
DOI : 10.1161/CIRCULATIONAHA.110.009449
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions, Circulation, vol.115, issue.17, pp.2344-51, 2007. ,
DOI : 10.1161/CIRCULATIONAHA.106.685313
WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction, Eur Heart J, vol.28, pp.2525-2563, 2007. ,
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial, European Heart Journal, vol.30, issue.14, pp.1753-63, 2009. ,
DOI : 10.1093/eurheartj/ehp159
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial, European Heart Journal, vol.32, issue.7, pp.838-884, 2011. ,
DOI : 10.1093/eurheartj/ehq494
Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel, American Heart Journal, vol.162, issue.4, pp.733-742, 2011. ,
DOI : 10.1016/j.ahj.2011.07.026
Residual Platelet Reactivity, Bleedings, and Adherence to Treatment in Patients Having Coronary Stent Implantation Treated With Prasugrel, The American Journal of Cardiology, vol.109, issue.2, pp.214-222, 2012. ,
DOI : 10.1016/j.amjcard.2011.08.034
Recent advances in the pharmacogenetics of clopidogrel, Human Genetics, vol.345, issue.Suppl. 2, pp.653-64, 2012. ,
DOI : 10.1007/s00439-011-1130-6
Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting, Archives of Cardiovascular Diseases, vol.103, issue.1, pp.39-45, 2010. ,
DOI : 10.1016/j.acvd.2009.11.004
Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation, JAMA, vol.303, issue.8, pp.754-62, 2010. ,
DOI : 10.1001/jama.2010.181
A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non???ST-Segment Elevation Acute Coronary Syndromes, Journal of the American College of Cardiology, vol.48, issue.5, pp.931-939, 2006. ,
DOI : 10.1016/j.jacc.2006.04.090
INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450, Drug Metabolism and Disposition, vol.34, issue.4, pp.600-607, 2006. ,
DOI : 10.1124/dmd.105.007989
Impact of ???Nuisance??? Bleeding on Clopidogrel Compliance in Patients Undergoing Intracoronary Drug-Eluting Stent Implantation, The American Journal of Cardiology, vol.102, issue.12, pp.1614-1621, 2008. ,
DOI : 10.1016/j.amjcard.2008.07.063
Rate of Nuisance Bleedings and Impact on Compliance to Prasugrel in Acute Coronary Syndromes, The American Journal of Cardiology, vol.108, issue.12, pp.1710-1713, 2011. ,
DOI : 10.1016/j.amjcard.2011.07.038
Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis, JAMA, vol.306, issue.16, pp.1765-74, 2011. ,
DOI : 10.1001/jama.2011.1529
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome, Thrombosis and Haemostasis, vol.103, issue.1, pp.213-236, 2010. ,
DOI : 10.1160/TH09-07-0482
Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes, Journal of the American College of Cardiology, vol.56, issue.13, pp.1017-1040, 2010. ,
DOI : 10.1016/j.jacc.2010.02.072